A Randomized, 5-Period, 5-Treatment, Single-Dose, Open-Label, Single-Center, Crossover Study to Estimate the Effect of AZD5718 on the Pharmacokinetics of Rosuvastatin, and to Assess the Relative Bioavailability of AZD5718 Oral Suspension vs AZD5718 IR Tablet Formulation and the Food Effect of AZD5718.
Phase of Trial: Phase I
Latest Information Update: 14 Mar 2017
At a glance
- Drugs AZD 5718 (Primary) ; AZD 5718 (Primary) ; Rosuvastatin (Primary)
- Indications Coronary artery disease
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 08 Mar 2017 Status changed from active, no longer recruiting to completed.
- 27 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 04 Jan 2017 Status changed from not yet recruiting to recruiting.